17 December 2021
Oxford BioDynamics confirms availability of EpiSwitch® CST (COVID Severity Test) and provides update on clinical validation of EpiSwitch® CiRT (Checkpoint Inhibitor Response Test)

17 December 2021
NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders

16 December 2021
Poolbeg Pharma agrees terms to develop an oral vaccine delivery platform

15 December 2021
First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001

08 December 2021
FuturaGene Secures License to CRISPR-Cas9 Technology to Develop Sustainable Varieties of Eucalyptus with Improved Productivity, Stress Resistance and Fiber Quality

06 December 2021
Poolbeg signs Option Agreement with University College Dublin for a Melioidosis Vaccine candidate, MelioVac, and a licence to evaluate 5 other infectious disease portfolio assets

30 November 2021
SkinBioTherapeutics plc - Full year results 2021

23 November 2021
ieso raises $53m to address global mental health crisis with digital therapeutics

19 November 2021
Touchlight Ranked Number Four Fastest Growing Technology Company in the UK in the 2021 Deloitte Technology Fast 50

18 November 2021
Poolbeg Pharma plc- Update on POLB 001 Clinical Development

16 November 2021
GHO Capital acquires Genesis Research, a pioneer in tech-enabled Real-World Evidence and HEOR services

16 November 2021
NorthSea Therapeutics- Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity

15 November 2021
HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtual Healthcare Conference

15 November 2021
Merit to build UK’s first CAR-T cell manufacturing facility in Stevenage for Autolus Therapeutics

15 November 2021
SkinBioTherapeutics - Placing of shares held by major shareholder

10 November 2021
HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights

10 November 2021
HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on clinical data updates across its novel arenaviral platform

03 November 2021
HOOKIPA Pharma to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

29 October 2021
World Psoriasis Day: AxisBiotix-Ps™, food supplement targeting psoriasis symptoms launches today

28 October 2021
UK patient participates in first Panthera@theRutherford trial for prostate cancer

27 October 2021
DNAe, Imperial College London and the University of Leicester collaborate on early detection of recurrent breast cancer

26 October 2021
GHO Capital invests in Sanner Group, a leading global supplier of high-quality active packaging solutions and components for the Pharmaceutical, Diagnostic, Nutraceutical and MedTech industries

21 October 2021
Crescendo Biologics announces that Zai Lab has achieved proof-of-concept for ZL-1102 (Humabody®, CB001) in a Phase 1b clinical trial in psoriasis patients

21 October 2021
VarmX awarded funding from the EIC Accelerator to support scale up and manufacturing of VMX-C001

21 October 2021
Crescendo Biologics announces prestigious new collaboration with The Institute of Cancer Research, London

15 October 2021
Touchlight to break ground on world’s highest-capacity DNA manufacturing facility

14 October 2021
HOOKIPA announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in Oncology

14 October 2021
Poolbeg Pharma plc- PredictViral™ Patent update

12 October 2021
Mission Therapeutics Awarded Follow-On Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation

11 October 2021
Mission Therapeutics to participate in the Solebury Trout Fall Private Company Showcase 2021

07 October 2021
Poolbeg Pharma plc- RNA sequencing ahead of pioneering AI analysis programme

30 September 2021
SkinBioTherapeutics plc - AxisBiotix-Ps™ Psoriasis Food Supplement Launch and Progress Update

28 September 2021
Oxford BioDynamics moves into new 24,000 sq ft tailor-made facility to support ongoing growth

21 September 2021
Touchlight expands commercial team amid rapid company growth

20 September 2021
Rutherford Health launches first community diagnostics hub of its kind in the UK, with another four planned

15 September 2021
HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers

15 September 2021
Touchlight extends funding round to US$125M as demand for its dbDNA™ grows rapidly

09 September 2021
BioFactura announces MTA with Rani Therapeutics

09 September 2021
Andrew Welchman leaves Wellcome Trust to lead impact at Ieso

08 September 2021
Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

02 September 2021
Ardena acquires Idifarma from Suanfarma and Sodena, adding spray drying technology and high potency capabilities

02 September 2021
Clinova unveils enhanced version of Caidr 3.0 – the health and wellness search engine for smart self-care

01 September 2021
GHO Capital invests in ClearView Healthcare Partners, the leading provider of strategic consulting services to global innovators in the life sciences

31 August 2021
Ixaka to present in vivo gene delivery platform for CAR-T and related bioproduction challenges at 6th CAR TCR Summit

31 August 2021
Rutherford Health Plc (“Rutherford” or “the Company”) Placing and Share Issue to acquire PPI UAE

31 August 2021
Oxford BioDynamics awarded US FNIH Grant to apply EpiSwitch® Immune Health test for improved prediction of patient response to Immune Checkpoint Inhibitor (ICI) cancer therapies

25 August 2021
Vitruvian Partners Announces Acquisition of Fotona from AGIC Capital

19 August 2021
SkinBioTherapeutics plc - Business Update

12 August 2021
HOOKIPA Pharma Reports Second Quarter 2021 Financial Results and Recent Highlights

09 August 2021
Partnership with OncoDNA to provide Rutherford patients with genomic testing

09 August 2021
Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone

04 August 2021
Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline

02 August 2021
Ixaka appoints Laurent Audoly as a Non-Executive Director

28 July 2021
Touchlight and Vanderbilt University Medical Center collaborate on DARPA Pandemic Prevention Platform programme to develop synthetic DNA-based antibody to protect against emerging threats

27 July 2021
CatSci and Argonaute RNA partner to expedite oligonucleotide manufacturing for gene-silencing therapeutics

22 July 2021
Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies

22 July 2021
Merit tops off winning streak with place on £1.6bn NHS modular construction framework

20 July 2021
GHO Capital announces final close of Fund III with over €2 billion of capital to invest

19 July 2021
VarmX to Present New Data on Lead Compound, VMX-C001, at the ISTH 2021 Virtual Congress

12 July 2021
FDA Grants Orphan Drug Designation for pridopidine for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

08 July 2021
Prilenia’s Phase 3 Huntington’s Disease Clinical Trial Achieves 50% Enrollment

07 July 2021
Enthera Pharmaceuticals opens early drug discovery unit at OpenZone life sciences campus to expand autoimmune disease research

29 June 2021
Prilenia receives positive EMA opinion on Orphan Drug Designation for pridopidine in ALS

29 June 2021
Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent’s Pipeline

29 June 2021
Ieso Digital Health granted U.S. patent for use of AI and tech to improve mental health provision

29 June 2021
Ixaka and SomaLogic enter research collaboration to develop bispecific agents for oncology

28 June 2021
DNAe Appoints Alison Howie as Vice President of Commercial

23 June 2021
Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology

15 June 2021
VectorY raises €31 million in seed financing to develop next-generation gene therapies aimed at muscular and CNS disorders

15 June 2021
VectorY strengthens leadership with appointments of new CEO and CTO

15 June 2021
VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board

15 June 2021
Oxford BioDynamics Plc - Half Year Results

08 June 2021
CatSci opens new Dagenham laboratory dedicated to analytical excellence

08 June 2021
HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers

07 June 2021
Agendia’s MammaPrint® Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial

05 June 2021
Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers

26 May 2021
SkinBioTherapeutics plc - Positive data for AxisBiotix-Ps™ food supplement consumer study unveiled

26 May 2021
Ysios Capital closes its third fund at €216 million ($260 million)

25 May 2021
BioFactura announces initiation of Phase I study of BFI-751, a Stelara® (ustekinumab) biosimilar

21 May 2021
First Patient Treated in Polyganics’ ENCASE II Trial for Innovative Dura Sealant Patch, LIQOSEAL®

20 May 2021
HOOKIPA to present Phase 1 safety, tolerability and preliminary anti-tumor activity data on HB-201 and HB-202 for the treatment of advanced HPV16+ cancers at ASCO

20 May 2021
Crescendo Biologics announces initiation of Phase 1 study of CB307 in patients with advanced, PSMA-positive solid tumours

20 May 2021
Validant acquires Clinical Outcomes Solutions, a global leader in clinical outcomes assessment research services

19 May 2021
Ieso - Depression subtypes linked to varying recovery rates, study shows

18 May 2021
Forbion expands team with new General Partner

13 May 2021
DNAe Appoints Richard Hammond as Vice President of Technology

10 May 2021
Crescendo Biologics further strengthens leadership team with appointment of Dr Michael Booth as Chief Financial Officer

05 May 2021
Alchemab to collaborate with AstraZeneca to use Alchemab’s drug discovery platform for prostate cancer study

04 May 2021
Engitix Therapeutics appoints Dr Mike Burbridge as VP Oncology and Immuno-oncology

28 April 2021
SkinBioTherapeutics initiates new oral health development programme in partnership with the University of Manchester

27 April 2021
CatSci commissions new material science lab as part of ambition to integrate medicines development

22 April 2021
Mission Therapeutics to Participate in Upcoming SVB Leerink Biopharma Private Company Connect Event

20 April 2021
Validant acquires Greenleaf Health, leading FDA regulatory consulting firm

19 April 2021
Ixaka appoints Christian Hoyer Millar as a Non-Executive Director

15 April 2021
Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics

12 April 2021
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers

08 April 2021
Clinigen launches Managed Access Program with BeiGene for zanubrutinib

06 April 2021
Clinigen to begin supplying Erwinase® in the UK

01 April 2021
Enthera Pharmaceuticals appoints Claudia Nardini as Vice President of Research and Development

31 March 2021
Oxford BioDynamics signs supply and resale agreement with Agilent Technologies, and launches EpiSwitch® Explorer Array Kit for R&D use

30 March 2021
Leiden University Medical Center and Ixaka enter collaboration to strengthen knowledge of cell therapy candidate REX-001

29 March 2021
New report reveals links between Covid-19 and the microbiome

29 March 2021
Clinigen Joins Decentralized Trials & Research Alliance (DTRA)

25 March 2021
Scientific paper by NutriLeads shows that its plant-based RG-I food ingredients support immune function and modulate the microbiota

24 March 2021
Mission Therapeutics Welcomes Co-founder of Rosetta Capital, Jonathan Hepple, to its Board of Directors

23 March 2021
Rutherford Health Plc - £40m Infrastructure Investment

23 March 2021
Oxford BioDynamics announces US launch of its EpiSwitch® COVID-19 Severity Test (CST)

22 March 2021
Ieso - largest ever analysis of digital mental health conversations reveals anxiety levels have continued to climb throughout the pandemic

18 March 2021
HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Outlook

17 March 2021
Oxford BioDynamics publishes results of biomarker discovery program being used for development of its EpiSwitch® Covid-19 Severity Test

17 March 2021
Forbion co-leads oversubscribed $53M Series B round for Amphista Therapeutics

16 March 2021
Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease

15 March 2021
Clinigen signs distribution agreement with Amgen in territories across Africa and Asia

15 March 2021
SkinBioTherapeutics plc - Half year consolidated results

11 March 2021
Revolutionary anti-viral face mask kills 99.9% of Covid-19 virus on contact

11 March 2021
Touchlight raises £42M ($58M) to meet unprecedented global DNA demand

04 March 2021
Pre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics published in Cell Reports Medicine

04 March 2021
Autifony Therapeutics, Boehringer Ingelheim to collaborate on novel ion channel target with potential in multiple disease areas related to lysosomal storage disorders

04 March 2021
Ieso Appoints Jo Parfrey as a Non-Executive Director

01 March 2021
Forbion leads $37M financing for Oxular

24 February 2021
Microbiotica Appoints Hans Schikan as Independent Non-Executive Chairman

23 February 2021
Engitix Therapeutics strengthens management team with new directors for fibrosis and computational biology

23 February 2021
Clinigen - Half Year Results

18 February 2021
SkinBioTherapeutics plc - AxisBiotix-Ps™ food supplement consumer study commences

15 February 2021
Clinigen partners with Karyopharm to distribute XPOVIO® (selinexor) to patients outside of the United States as part of a Named Patient Program

10 February 2021
Forbion launches VectorY, a novel gene therapy company to develop innovative vectorized antibodies

10 February 2021
Launch of novel gene therapy company, VectorY, to develop innovative vectorized antibodies

09 February 2021
Seventure Partners - Health for Life Capital II™ fund, managed by Seventure Partners, makes two new immuno-oncology (I/O) investments

08 February 2021
Ixaka strengthens IP Portfolio for its in vivo gene delivery platform and multi-cell therapy with key European and US patents

04 February 2021
Microbiotica expands management team with appointments of Chief Medical Officer and Chief Operating Officer

04 February 2021
GHO appoints David Miller and Geoffrey Hamilton-Fairley as Operating Partners

01 February 2021
SkinBioTherapeutics plc - Expanded enrolment for AxisBiotix-Ps™ food supplement consumer study

28 January 2021
Enthera Pharmaceuticals extends Series A financing, raising a total of €35m

28 January 2021
Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease

28 January 2021
Oxford Biodynamics Plc - Full Year Results

27 January 2021
VarmX appoints Dr. Gerard Short as Chief Medical Officer

26 January 2021
X-Chem acquires IntelliSyn and sister company, AviSyn, to extend and streamline drug discovery service range

26 January 2021
Clinigen receives marketing approval for Hunterase (Idursulfase-beta) ICV in Japan

21 January 2021
Xellia Pharmaceuticals joins Medicines for Europe to support better access to critical medicines

18 January 2021
Seventure Partners Life Sciences Corporate Update Health for Life: October - December 2020

18 January 2021
Ixaka (formerly Rexgenero) launches as an integrated cell and gene therapy company

14 January 2021
Forbion portfolio company, NewAmsterdam Pharma completes €160M Series A Funding for Phase 3 Development Program

14 January 2021
Clinigen Group plc - Half Year trading update

13 January 2021
SkinBioTherapeutics plc - Enrolment for AxisBiotix-Ps™ food supplement consumer study commences

11 January 2021
Health for Life Capital Fund, managed by Seventure Partners, increases focus on skin microbiome in its portfolio

08 January 2021
Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS

08 January 2021
NorthSea Therapeutics - Positive Phase 2b ICONA interim results for icosabutate in NASH patients

07 January 2021
BioGeneration Ventures BGV IV fund closes at €140 million

07 January 2021
Synthon BV Appoints Anish Mehta as Chief Executive Officer and Member of the Board of Directors